News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|July 4, 2024

Topical Ruxolitinib in Vitiligo: Efficacy, Regional Approvals, and Treatment Strategies in African American Patients

Author(s)Latanya Benjamin, MD, FAAD, FAAP

Dr. Latanya Benjamin, MD, FAAD, FAAP, discusses the role of topical ruxolitinib cream in managing vitiligo and its effectiveness in a 25-year-old female patient.

Episodes in this series

Latanya Benjamin, MD, FAAD, FAAP, an expert on vitiligo

EP. 1 Patient vs Provider Perceptions: Expert Opinions on Addressing the Emotional Impact of Vitiligo

Latanya Benjamin, MD, FAAD, FAAP, an expert on vitiligo

EP. 2 Vitiligo in a 35-Year-Old Female: Case-Based Discussion, Treatment Sequencing, and Practical Insights

Latanya Benjamin, MD, FAAD, FAAP, an expert on vitiligo

EP. 3 Vitiligo Case-Based Discussion: Impact of Stigma, Social Perception, and Practical Management Strategies

Latanya Benjamin, MD, FAAD, FAAP, an expert on vitiligo

EP. 4 Topical Ruxolitinib in Vitiligo: Efficacy, Regional Approvals, and Treatment Strategies in African American Patients

EP. 5 Vitiligo Care Personalized for Each Patient: Part 2

EP. 5 Vitiligo Care Personalized for Each Patient: Part 2

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Site-Specific MED Variability Guides 308-nm Excimer Laser Dosing

ByMaddi Hebebrand, MC, Associate Editor

December 10th 2025

Impaired HRQoL and High Psychological Comorbidity Observed in Japanese Vitiligo Patients

ByMarie Bosslett, Assistant Editor

December 10th 2025

AI at the Bedside: How Automated Solutions are Transforming Vitiligo Management

ByMarie Bosslett, Assistant Editor

December 9th 2025

Clear Communication Helps Reduce Patient Concerns About Boxed Warnings

ByMichael Lewitt, MD ,Maddi Hebebrand, MC, Associate Editor

November 25th 2025

Lewitt Highlights Early Treatment Benefits of Topical JAK Inhibitors

ByMichael Lewitt, MD ,Maddi Hebebrand, MC, Associate Editor

November 20th 2025

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population

Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC

First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA

Phase 2 Nemolizumab Trial Opens for CPUO

Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1

© 2025 MJH Life Sciences^®

All rights reserved.